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Abstract 
Background: While machine learning-based models are rapidly emerging as promising screening tools in 
critical care medicine, the identification of homogeneous subphenotypes within populations with 
heterogeneous conditions such as pediatric sepsis may facilitate attainment of high-predictive performance 
of these prognostic algorithms. This study is aimed to identify subphenotypes of pediatric sepsis and 
demonstrate the potential value of partitioned data/subtyping in predictive analytics. 
Methods: This was a retrospective study of clinical data extracted from medical records of 6,446 pediatric 
patients that presented to emergency departments and were admitted at a major hospital system in the 
Washington DC area.  Vitals and labs associated with patients meeting the diagnostic criteria for sepsis in 
this cohort were used to perform latent profile analysis.  Gradient boosted machine and random forest 
algorithms were used to explore the predictive performance benefits of reduced training data heterogeneity 
via label profiling.  
 
Results: In total 134 (2.1%) patients met the diagnostic criteria for sepsis in this cohort and latent profile 
analysis identified four profiles/subphenotypes of pediatric sepsis.  Profiles 1 and 3 had the lowest 
mortality and included pediatric patients from different age groups. Profile 2 patients were characterized by 
respiratory dysfunction while profile 4 patients characterized by neurological dysfunction (lowest total 
Glasgow Coma Score) and highest mortality rate (22.2%). Multiple machine learning experiments 
comparing the predictive performance of models derived without training data profiling against profile 
targeted models suggest statistically significant improved performance of prediction can be obtained.  For 
example, area under ROC curve (AUC) obtained to predict profile 4 with 24-hour data (AUC = .998, p < 
.0001) compared favorably with the AUC obtained from the model considering all profiles as a single 
homogeneous group (AUC = .918) with 24-hour data. 
 
Conclusion: This study utilized LPA to identify four clinically meaningful pediatric sepsis subphenotypes 
in training data and, for two of these subclasses with the highest mortality, derived statistically significant 
enhanced predictive models on the partitioned data. These experiments suggest that LPA is an applicable 
tool useful in analyzing heterogeneous pediatric sepsis to identify subphenotypes beneficial for building 
enhanced predictive pediatric sepsis models. Additional studies with larger data samples are needed to 
validate our findings. 
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1 Introduction 
The early recognition and management of sepsis remain among the greatest challenges in pediatric 
emergency medicine [1]–[3]. Sepsis is directly responsible for more than 4,000 childhood deaths per year in 
the U.S. and globally is associated with more than 6 million neonatal and early childhood deaths [4]–[6]. 
One-third of children who die in pediatric intensive care units (PICUs) within the U.S. have severe sepsis 
[7]. Excluding newborn and maternal stays, in 2012 there were approximately 1.8 million pediatric hospital 
admissions in the U.S., with an aggregated hospital annual cost of more than $20B [8].  Over 70% of these 
hospitalizations occurred in general hospitals as opposed to freestanding children’s hospitals. [9]  
Early recognition and timely, aggressive therapy are of pivotal importance to improve the outcomes of 
pediatric sepsis patients [1]–[5]. However the automated discrimination of the critically ill from normal 
pediatric patients presenting with abnormal temperature in the emergency department (ED) is challenging 
for several reasons [14][15]. Current pediatric sepsis screening tools are largely based on systemic 
inflammatory response syndrome (SIRS) criteria [16], designed to maximize sensitivity, while exhibiting 
poor specificity [17] and positive predictive value (PPV) [18], prompting modifications to improve 
specificity and PPV [19]. Although the recent consensus-based redefinition of adult sepsis (Sepsis-3) [20] 
selected the sequential organ failure assessment (SOFA) scoring system to address poor SIRS specificity, 
the derivation and validation of age-adjusted SOFA based screening tools for use in pediatrics [21] remain 
incomplete. Supervised machine learning (ML) sepsis predictive algorithms with the potential to improve 
the screening performance of rule-based systems have been proposed [22] [23], while generally limited by 
lack of large samples of high quality training data [23], i.e. accurately identified sepsis.  Moreover, sepsis is 
highly heterogeneous, with variable clinical presentations depending on the initial site of infection, the stage 
of sepsis at presentation, causative organism, pattern of acute organ dysfunction (OD), and underlying health 
status of the patient [24].  Such heterogeneity in population implies heterogeneity in relationships between 
explanatory and response variables within partitions, potentially posing serious challenges in predictive 
model building seeking to identify common explanatory data patterns in observed data associated with an 
outcome [25].  
The basic concept of precision medicine is the identification of subphenotypes of patients based on 
characteristics such as medical history, genetic makeup or electronic health record data (EHR), that will 
respond to subgroup-targeted personalized drugs or treatments [26]. Many efforts have been made to identify 
sepsis subphenotypes by using genomics and transcriptomics [27]. While genotyping is not currently 
routinely performed in daily clinical practice, recent large cohort studies indicate that unsupervised clustering 
analytics using routinely available clinical data extracted from EHRs may be useful to identify clinically 
useful partitions towards reducing heterogeneity in syndromic diseases.   Specifically, well-validated mixture 
modeling statistical techniques such as  Latent Class Analysis (LCA) [28] and Latent Profile Analysis (LPA) 
[29]-[30] that aim to recover hidden groups within observed data have been used with readily available 
clinical data to detect potentially useful subphenotypes associated with different mortality outcomes and 
response to treatment in adult sepsis [31] [32] and acute respiratory distress syndrome (ARDS) [33].  
To our knowledge, current ML algorithms used to predict sepsis do not yet target homogeneous 
subphenotypes in sepsis populations, and in general ignore most of existing sepsis domain knowledge [34]. 
The predictive performance benefits of incorporating prior knowledge such as subphenotype diversity into 
modern ML algorithms are not well understood [35].  
In this study, we integrate prior knowledge of the heterogeneity in a pediatric sepsis population into 
predictive model building by identifying subphenotypes that share common underlying pathophysiology as 
statistically expressed in observed clinical data (e.g. vitals signs, laboratory measurements). Specifically, 
we hypothesize that using  LPA-identified subphenotypes of sepsis subjects [32] in training data to build 
predictive models on more homogeneous partitioned data [25] will result in improved predictive validity 
when compared to models derived from treating all patients as a single homogeneous group. Prior work has 
demonstrated the value of problem domain classification semantics in the enhancement of mortality risk 
predictive models [36].  For pediatric sepsis LPA and predictive modeling, following IRB approval, we 
retrospectively analyzed data abstracted from medical records of 6,446 pediatric patients presenting to one 
of six MedStar Health System admitting facilities in the DC-Baltimore metropolitan area that occurred from 
2013-2018.  The median age of this cohort was 9 years with an average length of stay (LOS) of 85.49 hrs.   
2 Methods and Results: LPA  
   
2.1 Data for Latent Profile Analysis 
For this study, sepsis was defined as a life-threatening organ dysfunction caused by a dysregulated host 
response to infection per Sepsis-3 definition [20].  To identify sepsis cases we adopted the method used by 
Zhang [32], and screened for patients with documented or suspected infection, plus the presence of  organ 
dysfunction.  ICD diagnosis codes for a bacterial or fungal infection were used to define infection (see Table 
A3 in Appendix for SQL used to detect ICD-9 infection codes Zhang [32]; ICD-10 equivalents were used 
for post-2015 encounters).  Similarly ICD diagnosis and/or procedure codes (identifying mechanically 
ventilated patients) were used to identify organ dysfunction [32]. A patient was defined to have organ 
dysfunction if he or she had ICD-9 code (or ICD-10 equivalents) as follows: unspecified thrombocytopenia 
(287.5), hypotension (458.9), acute and subacute necrosis of liver (570), acute kidney failure (584.9), anoxic 
brain damage (348.1), shock without mention of trauma (785.59), encephalopathy (348.30), transient mental 
disorders due to conditions classified elsewhere (293.9), secondary thrombocytopenia (287.49), other and 
unspecified coagulation defects (286.9), defibrination syndrome (286.6), and hepatic infarction (573.4). If 
mechanical ventilation (procedures ICD code: 96.70, 96.71, 96.72) was required, it was also defined as 
organ dysfunction.   
 
Using the definition, 134 (2.1%) of the 6446 pediatric patients meet the diagnostic criteria for sepsis.  In 
seeking pediatric sepsis subphenotypes, we sought to use clinical features following onset in our LPA 
analysis.  The determination of time points of sepsis onset for sepsis patients was based on age-adjusted 
SOFA criteria [21], shown as a concept map in Fig. 1. Onset time was defined as the time when any 
component in age-adjusted SOFA was found abnormal.    
 
 
2.2 Latent Profile Analysis 
All available post-onset clinical data and lab measurements of 134 sepsis patients were considered as 
profile-defining variables in the LPA modelling; profiling was conducted without consideration of clinical 
outcomes. Details on clinical variable selection, data cleaning and a complete list of the clinical variables 
included in the LPA models are listed in Table 1. Unless specified, medians of measurements were 
extracted. Median imputation was applied to each variable with missing values. Given the small sample size 
we were unable to exclude features with large amounts of missing data. To select a model fitting the data best, a 
series of Latent profile models with different number of components are fitted, and Bayesian Information 
Criteria (BIC) is used for model selection [37]. 
Latent profile model estimation is based on Gaussian finite mixture modelling methods [38]. It assumes that 
the population is composed of a finite number of components. Mixture model parameters, i.e. components’ 
Figure 1 Sepsis-3 criteria concept map: Age-adjusted SOFA score 
means, covariance structure, and mixing weights, are obtained via the expectation maximization (EM) 
algorithm. Before LPA modeling, Yeo-Johnson power transformation [39] is applied to ensure approximate 
normality of continuous variables.   
 
Variable %missing Mean SD Min Median Max 
Age, yrs. 0.0 10.3 7.2 0.0 11.5 18.0 
Bicarbonate, mmol/L 3.7 21.1 5.5 5.0 22.0 44.0 
Bilirubin, mg/dL 17.2 3.0 6.9 0.1 0.6 39.3 
Chloride, mmol/L 3.7 106.7 6.6 88.0 106.0 128.0 
Creatinine, mg/dL 3.7 0.8 0.5 0.2 0.7 3.7 
GCS 46.3 11.2 4.5 3.0 14.0 15.0 
Eye Opening Response, GCS 46.3 2.8 1.3 1.0 3.0 4.0 
Best Motor Response, GCS 46.3 4.8 1.8 1.0 6.0 6.0 
Best Verbal Response, GCS 46.3 3.5 1.9 1.0 5.0 5.0 
Glucose mg/dL 79.1 164.8 107.1 70.0 125.0 600.0 
Hematocrit, % 3.0 34.4 6.7 15.2 34.5 51.0 
Heart rate, /min 9.0 119.5 29.9 50.0 119.5 195.0 
INR 35.1 1.6 0.9 0.9 1.3 5.8 
MAP, mmHg 2.2 77.6 17.2 43.7 78.3 131.0 
PaCO2, mmHg 64.9 39.4 11.2 10.0 39.0 71.0 
PaO2, mmHg 65.7 142.8 107.8 24.0 111.0 443.0 
pH 57.5 7.3 0.1 6.9 7.4 7.7 
Platelet, x109/L 3.0 224.9 150.5 8.0 210.5 821.0 
Potassium, mmol/L 3.7 4.1 0.8 2.6 4.0 6.9 
PTT, s 50.0 38.5 14.2 23.5 34.3 89.8 
Respiratory rate, /min 3.0 26.4 11.2 14.0 24.0 72.0 
Sodium, mmol/L 3.7 139.1 5.7 122.0 139.0 154.0 
Temperature, oC 23.9 37.4 1.1 35.7 37.0 40.0 
 
Table 1. Basic statistics of variable used in LPA 
 
2.3 LPA Results 
 
BIC criterion suggests a 4-component VEI model (i.e. diagonal, varying volume, and equal shape) fits the 
data best (Figure 2).  Numbers of patients assigned into subphenotypes are 33 in subphenotype 1, 35 in 
subphenotype 2, 39 in subphenotype 3, and 27 in subphenotype 4. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 and Fig. 3 (box plots of distribution of clinical features) shows differences in clinical features 
between profiles. Profiles 1 and 3 had the lowest mortality and included pediatric patients from different age 
groups. Profile 4 patients characterized by neurological dysfunction (lowest GCS total score) and highest 
mortality rate (22.2%); profile 2 characterized by respiratory dysfunction (low PaO2). Both profiles 2 and 4 
patients had significant more vasopressor use, while profile 2 patients had lowest mean blood pressure. 
 
 Variable, 
mean(SD)/median(IQR) 
Subphenotype 1 subphenotype 2 Subphenotype 3 Subphenotype 4 p 
n 33 35 39 27  
Age yrs.  15.48 (3.03)   8.91 (7.76)   3.44 (3.12)  15.67 (4.65) <0.001 
Platelet, x109/L 199.50 [144.75, 274.25] 177.00 [73.50, 329.00] 211.50 [116.75, 318.50] 216.00 [100.00, 288.00] 0.859 
PTT, s   35.40 [32.70, 37.00]  36.40 [33.50, 47.20]  33.00 [29.62, 36.75]  30.30 [26.85, 37.95] 0.242 
INR    1.20 [1.10, 1.30]   1.40 [1.30, 2.00]   1.20 [1.10, 1.30]   1.30 [1.20, 1.70] 0.003 
Creatinine*  -0.10 (0.13)  -0.24 (0.35)  -0.40 (0.24)  -0.06 (0.21) <0.001 
PaCO2, mmHg  37.50 (2.12)  36.80 (12.98)  59.00 (NA)  40.87 (9.25)  0.470 
PaO2*   1.96 (0.31)   1.93 (0.33)   2.25 (NA)   2.15 (0.27)  0.060 
Mean BP, mmHg   78.19 (12.83)  74.76 (20.98)  75.65 (14.53)  83.85 (19.44) 0.189 
Chloride, mmol/L  107.26 (4.53) 105.43 (8.78) 106.19 (5.37) 108.44 (6.82) 0.311 
pH    7.35 (0.05)   7.30 (0.18)   7.35 (0.10)   7.34 (0.16) 0.746 
Bicarbonate, mmol/L  22.58 (2.88)  19.63 (7.98)  21.39 (4.74)  20.81 (4.23) 0.172 
Hematocrit, %  34.06 (5.59)  33.83 (8.22)  33.03 (5.44)  37.36 (6.65) 0.065 
Temperature, oC  37.58 (1.11)  37.33 (1.06)  37.30 (1.07)  37.20 (1.04) 0.596 
Glucose, mg/dL 102.50 (4.95) 193.53 (133.64) 136.25 (41.96) 137.43 (65.11) 0.498 
Sodium, mmol/L 139.16 (3.80) 137.91 (7.58) 137.81 (4.65) 142.41 (5.03) 0.005 
Potassium, mmol/L   3.86 (0.50)   4.19 (0.89)   4.39 (0.96)   3.98 (0.73) 0.045 
HR, /min   98.73 (23.70) 133.38 (28.01) 128.36 (25.97) 113.46 (30.18) <0.001 
Figure 2 Models, number of profiles, and corresponding BIC. (See Appendix Table A1 for 
more information about model indices in legend). 
RR, /min  18.00 [18.00, 20.00]  30.00 [20.00, 39.75]  28.00 [24.00, 34.00]  17.50 [16.00, 28.25] <0.001 
Bilirubin, mg/dL   0.60 [0.40, 0.80]   0.70 [0.40, 3.65]   0.50 [0.30, 1.20]   0.50 [0.40, 0.80] 0.416 
Minimum GCS score   15.00 [15.00, 15.00]  14.00 [14.00, 15.00]  15.00 [14.00, 15.00]   6.00 [3.00, 9.00] <0.001 
GCS, min motor score   6.00 [6.00, 6.00]   6.00 [6.00, 6.00]   6.00 [6.00, 6.00]   4.00 [1.00, 5.00] <0.001 
GCS, min verbal score   5.00 [5.00, 5.00]   5.00 [5.00, 5.00]   5.00 [5.00, 5.00]   1.00 [1.00, 1.00] <0.001 
GCS, min eye score   4.00 [4.00, 4.00]   3.00 [3.00, 4.00]   4.00 [4.00, 4.00]   1.00 [1.00, 2.50] <0.001 
Dopamine, n (%)      0 (0.0)       8 (22.9)       0 ( 0.0)       4 (14.8)  <0.001 
Epinephrine, n (%)      2 (6.1)      13 (37.1)       9 (23.1)       9 (33.3)  0.01 
Phenylephrine, n (%)      0 (0.0)       3 ( 8.6)       0 ( 0.0)       9 (33.3)  <0.001 
Vasopressin, n (%)      0 (0.0)       2 ( 5.7)       0 ( 0.0)       4 (14.8)  0.009 
Death, n (%)      0 (0.0)       2 ( 5.7)       0 ( 0.0)       6 (22.2)  0.001 
 
Table 2 Simple Statistics between 4 subphenotypes Abbreviations: PTT partial thrombin time, BP blood pressure, GCS Glasgow 
Coma Scale, INR international normalized ratio, IQR interquartile ratio, PaCO2 partial pressure of carbon dioxide, PaO2 arterial 
partial oxygen pressure, pH potential hydrogen, SD standard deviation, HR heart rate, RR respiratory rate.    
 *: measurements are logarithmic transformed. 
 
 
 
 
 
 
 
 
Figure 3 Differences in clinical features by four subphenotypes 
3. Methods and Results: Predictive Modeling 
 
For predictive modeling, training data was partitioned into 4 groups according to profile assignment, and 
predictive models were developed and evaluated within these subphenotypes. For example, for the profile 1 
prediction we used 6312 non--septic cases as control data combined with the data of the 33 profile1 cases for 
a total of 6345 training samples. (Data from other profiles were excluded.)  The profile 1 predictive 
performance (against an independent test set) of these profile specific sepsis models were compared with the 
predictive performance achieved by including all profiles in training data and predicting "any" sepsis.  In 
effect we are comparing how accurately we can predict a sepsis subphenotype vs "any" sepsis which may 
be important if we can achieve higher performance prediction for a high-risk sepsis subphenotype (e.g. 
subphenotype 4) than for the sepsis population as a whole.          
 
3.1 Training Data for Predictive Modeling 
Non-septic patients of the 6446-patient cohort are used as negative controls in the predictive modeling. 
Features considered in the predictive model building include: 1) vital signs: heart rate, respiratory rate, body 
temperature, systolic blood pressure, diastolic blood pressure, GCS; 2) laboratory tests: ALT, AST, 
chloride, glucose, potassium, sodium, hematocrit, creatinine, PTT, INR, and platelet count; 3) blood gas 
measurements: pH, lactic acid, base deficit, bicarbonate, fraction of inspired oxygen, partial pressure of 
arterial oxygen, fraction of inspired oxygen, and partial pressure of arterial carbon dioxide. Four sets of 
features were extracted from data defined on different periods after admission: over first 6, 12, 24 hours 
following admission and over the whole length of stay. Table 3 shows simple statistics of features extracted 
over the whole length of stay. 
 
Feature %missing mean SD min median max 
Age 0.0 8.88 7.05 0 9 18 
ALT 54.7 49.78 128.88 3 24 3337 
AST 54.8 49.52 187.90 1.5 23 7794 
Base deficiency 90.5 -5.54 7.90 -30 -4 24 
Bicarbonate 19.1 23.13 4.21 2 24 44 
Bilirubin 54.3 1.16 3.06 0.05 0.4 39.3 
Chloride 19.0 105.49 3.77 72 106 134 
Creatinine 22.2 0.60 0.35 0.09 0.58 7.83 
DBP 1.8 51.87 9.76 0 52 113 
FIO2 87.0 50.47 30.11 1 40 100 
GCS 69.4 14.34 2.06 3 15 15 
Glucose 91.2 181.89 144.83 6 118 600 
Hematocrit 17.0 37.44 5.64 9 37.5 78 
HR 18.3 116.81 34.13 1 114 265 
INR 83.0 1.19 0.37 0.9 1.1 5.8 
Lactic Acid 86.1 1.94 1.61 0.35 1.5 12.6 
PaCO2 90.5 34.36 10.25 10.9 33.8 87 
PaO2 95.4 165.12 118.21 23.9 123 500 
pH 90.5 7.33 0.29 3.405 7.38 7.68 
Platelet 17.9 291.13 111.44 1 274 1215 
Potassium 19.1 4.15 0.67 1.2 4 8.6 
PTT 89.7 34.62 17.65 20 31.2 200 
RR 0.8 26.84 13.84 0 22 352 
SBP 1.8 95.61 16.07 0 96 167 
Sodium 18.9 138.44 3.45 54 139 163 
Temperature 25.8 37.00 0.95 6.7 36.9 41.1 
Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase, PTT partial thrombin time, DBP 
diastolic blood pressure, SBP systolic blood pressure, GCS Glasgow Coma Scale, INR international normalized ratio, 
FIO2 fraction of inspired oxygen, PaCO2 partial pressure of carbon dioxide, PaO2 arterial partial oxygen pressure, pH 
potential hydrogen, SD standard deviation, HR heart rate, RR respiratory rate.  
Table 3 Basic Statistics of Training Data Features.    
3.2 Predictive Models 
Predictive models, including gradient boosted machine (GBM) [40] and random forest (RF) [41], were built 
for all cases and each phenotype separately, with all non-sepsis subjects as the control group. Missing values 
were replaced by medians of each variables. Synthetic Minority Over-Sampling Technique (SMOTE) was 
applied to resample data [42]. Data was split into a training (70%) and test set (30%). Cross validation was 
used for tuning hyperparameters: number of trees, interaction depth, learning rate, minimum number of 
observations in nodes for GBM model; and number of trees for RF model. Tuned models were used to 
evaluate performance of predicting sepsis in the test set, and the model with best performance is selected. 
Confidence intervals of performance metrics were obtained by bootstrapping method [43]. To compare 
performance (e.g. AUC) between models, the method proposed by Delong et al. [44] was applied, with the 
null hypothesis that the true difference in performance metrics was equal to 0. 
   3.3 Predictive Model Results 
Predictive models were built for all cases and each phenotype separately. Performances of predictive models 
evaluated using validation set are listed in Table 4.  Model based on early 6- and 12-hour data generally 
yielded slightly poorer performance when comparing with models based on 24-hour and whole LOS data. 
Results also suggest that, providing sufficient data (e.g. 24 hours or longer stay data), significant 
improvements in AUC are obtained to predict phenotype 2 (p=0.0077 with 24-hour data, and p=0.0029 
with whole LOS data) and phenotype 4 (p<0.0001 with 24-hour data, and p=0.0014 with whole LOS data) 
when comparing with the AUC from the model considering all phenotypes together. As indicated by Table 
2, the two phenotypes are probably high-risk cases who used significantly more vasopressor, and phenotype 
4 also had the highest mortality. Importance of features in predicting phenotypes were found to be different 
across phenotypes (Appendix Table A2). GCS and FIO2 ranked top in predicting phenotype 4, while age 
and creatinine ranked top in predicting other phenotypes. 
  
Metric All Phenotypes  Phenotype 1 Phenotype 2 Phenotype 3 Phenotype 4 
Features extracted from data on the whole length of stay 
AUC 0.912(0.858 - 0.965) 0.959(0.912 - 1.0) 0.994(0.989 - 0.998) 0.927(0.867 - 0.987) 0.999(0.998 - 1.0) 
Sensitivity 0.925(0.8 - 1.0) 1(0.889 - 1.0) 1.0(1.0 - 1.0) 0.909(0.818 - 1.0) 1.0(1.0 - 1.0) 
Specificity 0.856(0.76 - 0.901) 0.928(0.763 - 0.983) 0.985(0.979 - 0.992) 0.928(0.709 - 0.95) 0.998(0.995 - 1.0) 
Accuracy 0.856(0.765 - 0.901) 0.928(0.764 - 0.983) 0.985(0.98 - 0.992) 0.928(0.711 - 0.95) 0.998(0.995 - 1.0) 
PPV 0.114(0.078 - 0.157) 0.059(0.02 - 0.209) 0.263(0.204 - 0.4) 0.066(0.02 - 0.094) 0.667(0.471 - 1.0) 
NPV 0.998(0.995 - 1.0) 1(0.999 - 1.0) 1.0(1.0 - 1.0) 0.999(0.999 - 1.0) 1.0(1.0 - 1.0) 
P value*  - 0.1947 0.0029 0.7189 0.0014 
      
Features extracted from data on the first 6 hours after admission 
AUC 0.879(0.826 - 0.932) 0.89(0.794 - 0.986) 0.931(0.861 - 1.0) 0.834(0.68 - 0.988) 0.984(0.961 - 1.0) 
Sensitivity 0.875(0.725 - 0.95) 0.889(0.667 - 1.0) 0.9(0.7 - 1.0) 0.727(0.455 - 1.0) 1.0(1.0 - 1.0) 
Specificity 0.807(0.775 - 0.888) 0.926(0.567 - 0.947) 0.847(0.627 - 0.967) 0.936(0.921 - 0.988) 0.906(0.89 - 0.994) 
Accuracy 0.809(0.777 - 0.886) 0.925(0.569 - 0.946) 0.848(0.628 - 0.966) 0.935(0.92 - 0.986) 0.906(0.89 - 0.994) 
PPV 0.089(0.073 - 0.133) 0.05(0.011 - 0.073) 0.033(0.014 - 0.127) 0.068(0.038 - 0.24) 0.043(0.037 - 0.4) 
NPV 0.997(0.993 - 0.999) 0.999(0.998 - 1.0) 0.999(0.998 - 1.0) 0.998(0.997 - 1.0) 1.0(1.0 - 1.0) 
P value* - 0.1678 0.1727 0.5119 0.0915 
      
Features extracted from data on the first 12 hours after admission 
AUC 0.885(0.836 - 0.933) 0.924(0.851 - 0.998) 0.9(0.764 - 1.0) 0.895(0.816 - 0.975) 0.989(0.974 - 1.0) 
sensitivity 0.875(0.675 - 1.0) 0.889(0.778 - 1.0) 0.9(0.6 - 1.0) 0.909(0.727 - 1.0) 1.0(1.0 - 1.0) 
specificity 0.772(0.624 - 0.931) 0.964(0.682 - 0.977) 0.871(0.847 - 0.999) 0.806(0.552 - 0.948) 0.943(0.93 - 1.0) 
accuracy 0.775(0.631 - 0.927) 0.963(0.683 - 0.976) 0.871(0.848 - 0.998) 0.806(0.554 - 0.947) 0.944(0.931 - 1.0) 
PPV 0.076(0.05 - 0.183) 0.1(0.015 - 0.153) 0.037(0.027 - 0.769) 0.028(0.013 - 0.082) 0.07(0.057 - 1.0) 
NPV 0.996(0.993 - 1.0) 0.999(0.999 - 1.0) 0.999(0.998 - 1.0) 0.999(0.998 - 1.0) 1.0(1.0 - 1.0) 
P value* - 0.3794 0.8358 0.831 <0.0001 
      
Features extracted from data on the first 24 hours after admission 
AUC 0.918(0.881 - 0.956) 0.922(0.851 - 0.994) 0.976(0.956 - 0.997) 0.944(0.893 - 0.995) 0.998(0.996 - 1.0) 
sensitivity 0.85(0.725 - 0.95) 0.889(0.778 - 1.0) 1.0(1.0 - 1.0) 0.909(0.818 - 1.0) 1.0(1.0 - 1.0) 
specificity 0.899(0.757 - 0.928) 0.882(0.646 - 0.971) 0.924(0.911 - 0.978) 0.904(0.697 - 0.964) 0.994(0.989 - 0.999) 
accuracy 0.898(0.759 - 0.926) 0.882(0.647 - 0.971) 0.924(0.911 - 0.978) 0.904(0.699 - 0.964) 0.994(0.989 - 0.999) 
PPV 0.149(0.073 - 0.195) 0.036(0.013 - 0.127) 0.065(0.056 - 0.192) 0.054(0.019 - 0.133) 0.421(0.276 - 0.889) 
NPV 0.996(0.994 - 0.999) 0.999(0.999 - 1.0) 1.0(1.0 - 1.0) 0.999(0.999 - 1.0) 1.0(1.0 - 1.0) 
P value* - 0.9217 0.0077 0.4215 <0.0001 
*: P value is from AUC comparisons, in which “All phenotypes” is the reference AUC.  
 Table 4 Comparative performance between subphenotype-specific and all sepsis phenotype prediction 
4. Discussion 
Using routinely available clinical variables this study applied LPA clustering to group pediatric sepsis 
patients to identify four latent profiles (i.e. homogeneous subphenotypes) and derived separate predictive 
models for each subphenotype. The predictive models performed better on specific subphenotypes of sepsis 
patients than on the sepsis cohort overall, thus supporting our primary hypothesis. Further, we found that, 
prediction was better in two specific subphenotype groups than in the other subphenotypes. Profile 4 patients 
were characterized by neurological dysfunction (lowest GCS total score) and highest mortality rate (22.2%); 
profile 2 characterized by respiratory dysfunction (low PaO2). Patients with profiles 2 and 4 had significant 
more vasopressor use, while profile 2 patients had lowest BP. Although our study did not focus on this issue, 
given ongoing concerns regarding the use of aggressive fluid management in some patients [45], the 
identification of these subphenotypes may help triage pediatric sepsis patients that respond differently to 
aggressive fluids treatment [32][46].  
 
At an AUC of .98 compared to AUC of .88 (p < .0001) for Profile 4 using data within 12 hours following 
admission, our results suggest that significantly improved performance of prediction can be obtained for 
pediatric sepsis subphenotypes at high risk of mortality. Although there are significant differences in 
physiology, underlying conditions, mortality rates and even prevalence of sepsis between pediatric and 
adults, a recent related study of adult sepsis also found four sepsis phenotypes with different demographics, 
laboratory values, and patterns of organ dysfunction, with treatment outcomes sensitive to changes in the 
distribution of these subphenotypes [47].     
 
 There are a number of ways to perform agnostic clustering, such as hierarchical cluster analysis, self-
organizing map, K-means consensus clustering [48], and latent class analysis (LCA) [28], [30], [49]. Latent 
class analysis (LCA) and latent profile analysis (LPA) are techniques that aim to recover hidden groups from 
observed data. They are similar to clustering techniques but more flexible because they are based on an 
explicit model of the data and allow you to account for the fact that the recovered groups are uncertain by 
deriving clusters using a probabilistic model that describes distribution of the data. So instead of looking for 
clusters with some arbitrary chosen distance measure, LPA fits a model that describes distribution of the 
data and based on this model you assess probabilities that certain patients are members of certain latent 
profiles.  LCA and LPA are useful when you want to reduce many continuous (LPA) or categorical (LCA) 
variables to a few subgroups. They can also help experimenters in situations where the treatment effect is 
different for subgroups, but the subgroups have not been identified [50].  For sepsis, LPA seems to be an 
appropriate clustering choice given the continuous variables underlying organ dysfunction and since it 
allows the modeling of a latent structure underlying the observed data (e.g. “dysregulated host response”) 
rather than just modeling similarities based on a distance metric (e.g. k-means clustering) [32].   
 
It is known that heterogeneity in population poses a great challenge to predictive modeling. First, the 
training data may be comprised of instances from not just one distribution, but several distributions 
juxtaposed together. In the presence of multimodality within the classes, there may be imbalance among the 
distribution of different modes in the training set. Hence, some of the modes may be underrepresented 
during training, resulting in poor performance on those modes during the testing stage. Second, while some 
of the modes of a particular class may be easy to distinguish from modes of the other class, there may be 
modes that participate in class confusion, i.e., reside in regions of feature space that overlap with instances 
from other classes. The presence of such overlapping modes can degrade the learning of any classification 
model trained across all modes of every class. Third, even if we are able to learn a predictive model that 
shows reasonable performance on the training set, the test set may have a completely different distribution of 
data instances than the training set, as the populations of training and test sets can be different. Hence, the 
training performance can be quite misleading as it may not always be reflective of the performance on test 
instances. For these reasons, identifying homogeneous subgroups within heterogeneous population mitigate 
the impact of population’s heterogeneity in predictive model building. Significant differences in importance 
of features across subphenotype predictive models (e.g. subphenotypes 2 and 4 as seen in Table A3 in the 
Appendix), compared to the entire cohort support this line of reasoning. 
 
Several limitations must be acknowledged in this study. First, this study used EHR data which were 
produced by routine clinical practice with significant missing data, although in many cases missing data may 
not be at random and training feature “missingness” may reflect clinical decisions that can be modeled [51] . 
As described above imputations were performed for variables containing missing values. Although there are 
many sophisticated methods to deal with missing values, significant bias may be introduced for those with 
missing rates greater than 40% [52]. For example, in this study the number of missing serum lactate 
observations was high while studies show that in children treated for sepsis in the emergency department, 
lactate levels greater than 36 mg/dL (4 mmol/L) were associated with mortality, but also had a low 
sensitivity, potentially explaining the level of “missingness”  [53].  While its use is not endorsed in pediatric 
sepsis guidelines [54], the measurement of lactate levels may have utility in early risk stratification of 
pediatric sepsis [53]. Second, although restricting the variables used for modeling to those available in 
clinical practice is reasonable, it may limit the separation of classes. It would be better to use biomarkers and 
genomics as well, since studies indicate they may contribute in pediatric sepsis subphenotyping [55]. 
Combining clinical data and biological data in LPA-based phenotyping may improve homogeneities of sepsis 
sub-phenotypes towards further enhancement of predictive performance of ML within subgroups. However, 
inflammatory or genetic biomarker biomarkers were not routinely obtained and therefore were not available 
in the MedStar database. Finally, the study was based on a relatively small sample size and requires external 
validation with other datasets.   
 
5. Conclusions 
Rapid protocolized treatment is known to improve sepsis outcomes, however especially in children, early 
diagnosis remains challenging due to age-dependent heterogeneity and complex presentation [56]. 
Moreover, there is growing recognition of the presence of sepsis subphenotypes identified by profiling 
clinical data that respond differently to treatment [47].  While promising machine learning models derived 
over large samples have the potential to accurately identify children with sepsis hours before clinical 
recognition [56], the potential benefits of incorporating sepsis subphenotype knowledge in training data is 
unknown. This study utilized LPA to identify four clinically meaningful pediatric sepsis subphenotypes in 
training data and, for two of these subphenotypes with the highest mortality, derived enhanced predictive 
models on the partitioned data. These experiments suggest that LPA is an applicable tool useful in analyzing 
heterogeneous pediatric sepsis to identify subphenotypes beneficial for building enhanced predictive 
pediatric sepsis models. Additional studies with larger data samples needed to validate our findings. 
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Abbreviations 
ALT: Alanine aminotransferase; ARDS: Acute Respiratory Distress Syndrome; AST: Aspartate 
aminotransferase; AUC: Area under receiver operating curve; BIC: Bayesian information criteria; BP: Blood 
pressure; CI: Confidence interval; DBP: Diastolic Blood Pressure; EHR: Electronic Health Record; EM: 
Expectation Maximization; GBM: Gradient Boosted Machine; GCS: Glasgow Coma Scale; HR: Heart Rate; 
ICD: International Classification of Diseases; ICU: Intensive care unit; INR: International normalized ratio; 
IQR: Interquartile range; IRB: Institutional review board; LCA: Latent class analysis; LOS: Length of stay; 
LPA: Latent profile analysis; MAP: Mean Arterial Pressure; ML: machine Learning; NPV: Negative 
Predictive Value; OD: Organ Dysfunction; PaCO2: Partial pressure of carbon dioxide; PaO2: Arterial partial 
oxygen pressure; pH: potential of Hydrogen; PICU: Pediatric Intensive Care Unit; PPV: Positive Predictive 
Value; PTT: Partial thrombin time; RF: Random Forest; ROC: receiver operating curve; RR: Respiratory 
rate; SBP: Systolic Blood Pressure; SD: Standard Deviation; SIRS: Systemic Inflammatory Response 
Syndrome; SOFA: Sequential organ failure assessment; VEI = diagonal, varying volume, equal shape. 
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Appendix 
 
Table A1 Identifiers used in Fig.2 
 
Identifier Distribution Volume Shape Orientation 
EII Spherical equal equal NA 
VII Spherical variable equal NA 
EEI Diagonal equal equal coordinate axes 
VEI Diagonal variable equal coordinate axes 
EVI Diagonal equal variable coordinate axes 
VVI Diagonal variable variable coordinate axes 
EEE Ellipsoidal equal equal equal 
EEV Ellipsoidal equal equal variable 
VEV Ellipsoidal variable equal variable 
VVV Ellipsoidal variable variable variable 
 
 
 
  
 
 
 
 
 
Table A2 Variable Importance in predicting phenotypes 
Importance 
rank 
All phenotypes   Phenotype 1   Phenotype 2   Phenotype 3   Phenotype 4 
Variable Score   Variable Score   Variable Score   Variable Score   Variable Score 
1 Age 100  Age 100  Age 100  Age 100  GCS 100 
2 Creatinine 66.93  Creatinine 63.4  RR 58.23  Creatinine 53.37  FIO2 45.64 
3 INR 29.16  Hematocrit 51.7  Base Deficiency 29.76  RR 31.44  Lactic Acid 40.37 
4 Base Deficiency 28.13  INR 51.31  PaO2 27.43  INR 24.11  Creatinine 15.4 
5 pH 27.21  RR 48.41  HR 20.75  ALT 19.19  INR 13.67 
6 Bicarbonate 26.81  Lactic Acid 41.77  pH 19.73  HR 17.99  PaO2 13.57 
7 AST 24.98  PTT 39.51  PaCO2 17.49  GCS 16.15  Sodium 7.48 
8 Lactic Acid 21.73  Platelet 39.45  INR 17.42  pH 14.99  PTT 6.49 
9 RR 19.03  Temperature 32.58  FIO2 16.79  AST 14.08  Age 4.49 
10 Chloride 18.97  HR 27.37  Bicarbonate 15.51  Potassium 12.3  Bilirubin 3.99 
11 Hematocrit 18.38  DBP 26.35  Bilirubin 13.86  Lactic Acid 11.6  AST 1.68 
12 ALT 15.94  Sodium 26.33  Creatinine 12.75  Base Deficiency 11.31  DBP 1.67 
15 PTT 12.76  AST 23.72  AST 11.56  Bicarbonate 9.78  Base Deficiency 1.57 
16 PaCO2 12.44  PaCO2 23.32  Temperature 11  PTT 9.75  Chloride 1.38 
17 Bilirubin 12.14  Chloride 22.7  Hematocrit 9.93  Temperature 7.32  Platelet 1.2 
18 HR 10.82  SBP 21.52  DBP 9.14  PaCO2 7.05  Potassium 1.05 
19 SBP 10.59  Potassium 18.99  Potassium 9.03  Hematocrit 6.74  RR 0.66 
22 FIO2 7.09  Bilirubin 12.71  ALT 7.51  Sodium 4.89  SBP 0.56 
23 Glucose 7.01  pH 9.91  Sodium 7.18  PaO2 4.71  Bicarbonate 0.53 
24 Sodium 3.25  FIO2 1.97  PTT 6.58  DBP 3.75  HR 0.31 
25 Potassium 1.12  PaO2 1.49  Platelet 5.61  SBP 3.27  Glucose 0.16 
26 Temperature 0   Glucose 0   Lactic Acid 0   FIO2 0   Temperature 0 
 
Table A3 ICD-9 Codes for Infection 
 
ICD-9 codes for infection:   
WITH infection_group AS  
(  
 SELECT subject_id, hadm_id,  
 CASE  
  WHEN substring(icd9_code,1,3) IN 
('001','002','003','004','005','008',  
    
'009','010','011','012','013','014','015','016','017','018',  
    
'020','021','022','023','024','025','026','027','030','031',  
    
'032','033','034','035','036','037','038','039','040','041',  
    
'090','091','092','093','094','095','096','097','098','100',  
    
'101','102','103','104','110','111','112','114','115','116',  
    
'117','118','320','322','324','325','420','421','451','461',  
    
'462','463','464','465','481','482','485','486','494','510',  
    
'513','540','541','542','566','567','590','597','601','614',  
    '615','616','681','682','683','686','730') THEN 1  
  WHEN substring(icd9_code,1,4) IN 
('5695','5720','5721','5750','5990','7110',  
    '7907','9966','9985','9993') THEN 1  
  WHEN substring(icd9_code,1,5) IN 
('49121','56201','56203','56211','56213',  
    '56983') THEN 1  
  ELSE 0 END AS infection  
 FROM diagnoses_icd 
 
